Quanterix Corporation logo QTRX - Quanterix Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 5
HOLD 5
SELL 0
STRONG
SELL 0
| PRICE TARGET: $4.00 DETAILS
HIGH: $4.00
LOW: $4.00
MEDIAN: $4.00
CONSENSUS: $4.00
UPSIDE: 0.50%

Stock News

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026, inducement grants (the “Inducement Grants”) were made to three employees in connection with the commencement of their employment. The Inducement Grants consisted of 336,804 restricted stock units (“RSUs”) representing 336,804 shares of Quanterix commo.

Jun 16, 2026 12:01 PM • businesswire.com
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer

Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry, positioning him to play a pivotal role in executing Quanterix's st.

Jun 09, 2026 04:03 AM • businesswire.com
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Al.

Jun 04, 2026 04:02 AM • businesswire.com
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Com.

Jun 03, 2026 04:01 AM • businesswire.com
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on May 15, 2026, an inducement grant (the “Inducement Grant”) was made to Anthony Catalano in connection with the commencement of his employment as the Chief Operating Officer of the Company. The Inducement Grant consists of restricted stock units (“RSUs”) covering 141.

May 26, 2026 12:01 PM • businesswire.com
Quanterix Announces Planned Transition of Chief Financial Officer

Quanterix Announces Planned Transition of Chief Financial Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer (“CFO”) will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026, to ensure continuity and a successful transition. "Vandana has made impactful contributions to Quanterix since joining the Co.

May 12, 2026 12:01 PM • businesswire.com
Quanterix Releases Financial Results for the First Quarter of 2026

Quanterix Releases Financial Results for the First Quarter of 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026. “We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition,” said Everett Cunningham, President & CEO of Quanterix. “As part.

May 06, 2026 12:01 PM • businesswire.com
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing.

May 06, 2026 04:00 AM • businesswire.com
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. Quanterix will issue a press release regarding its first quarter 2026 financial results prior to the conference call on Wednesday, May 6, 2026, after the market closes. T.

Apr 24, 2026 04:33 AM • businesswire.com
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)--PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager® HT platform using Opal™ chemistry. This marks a significant milestone in the clinical translation of spatial proteomics. The validation of AidaBREAST included 922 hormone recep.

Apr 17, 2026 04:33 AM • businesswire.com
Quanterix Debuts Content Innovation Engine at AACR 2026

Quanterix Debuts Content Innovation Engine at AACR 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. Built on the integration of Akoya Biosciences' spatial biology platform and Quanterix's decades of ultra-sensitive, quantitative immunoassay development from the SIMOA® technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a sys.

Apr 15, 2026 04:33 AM • businesswire.com
Quanterix Corporation Announces Date of 2026 Annual Meeting

Quanterix Corporation Announces Date of 2026 Annual Meeting

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Company's 2026 annual meeting of shareholders (the “Annual Meeting”) will be held virtually, by means of remote communication, on Tuesday, June 9, 2026 at 10:00 am Eastern Time. Stockholders of record of the Company's common stock as of the close of business on April 14, 2026 will be entitled to vote.

Mar 27, 2026 12:00 PM • businesswire.com
Analyzing Quanterix (NASDAQ:QTRX) & IM Cannabis (NASDAQ:IMCC)

Analyzing Quanterix (NASDAQ:QTRX) & IM Cannabis (NASDAQ:IMCC)

Quanterix (NASDAQ: QTRX - Get Free Report) and IM Cannabis (NASDAQ: IMCC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk. Institutional and Insider Ownership 86.5% of Quanterix shares

Mar 18, 2026 10:14 PM • defenseworld.net
Quanterix (NASDAQ:QTRX) vs. TREES (OTCMKTS:CANN) Head-To-Head Review

Quanterix (NASDAQ:QTRX) vs. TREES (OTCMKTS:CANN) Head-To-Head Review

TREES (OTCMKTS:CANN - Get Free Report) and Quanterix (NASDAQ: QTRX - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability. Profitability This table compares TREES and Quanterix's net margins,

Mar 08, 2026 09:30 PM • defenseworld.net

Price Targets